RARE vs. PRGO, ARWR, MRTX, ACAD, BHC, UTHR, VTRS, RDY, SRPT, and CTLT
Should you be buying Ultragenyx Pharmaceutical stock or one of its competitors? The main competitors of Ultragenyx Pharmaceutical include Perrigo (PRGO), Arrowhead Pharmaceuticals (ARWR), Mirati Therapeutics (MRTX), ACADIA Pharmaceuticals (ACAD), Bausch Health Companies (BHC), United Therapeutics (UTHR), Viatris (VTRS), Dr. Reddy's Laboratories (RDY), Sarepta Therapeutics (SRPT), and Catalent (CTLT). These companies are all part of the "pharmaceutical preparations" industry.
Perrigo (NYSE:PRGO) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, media sentiment, earnings, community ranking, analyst recommendations, profitability and risk.
95.9% of Perrigo shares are owned by institutional investors. Comparatively, 97.7% of Ultragenyx Pharmaceutical shares are owned by institutional investors. 0.4% of Perrigo shares are owned by insiders. Comparatively, 5.8% of Ultragenyx Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
In the previous week, Ultragenyx Pharmaceutical had 7 more articles in the media than Perrigo. MarketBeat recorded 11 mentions for Ultragenyx Pharmaceutical and 4 mentions for Perrigo. Ultragenyx Pharmaceutical's average media sentiment score of 1.19 beat Perrigo's score of 1.03 indicating that Perrigo is being referred to more favorably in the media.
Ultragenyx Pharmaceutical received 47 more outperform votes than Perrigo when rated by MarketBeat users. Likewise, 77.16% of users gave Ultragenyx Pharmaceutical an outperform vote while only 66.78% of users gave Perrigo an outperform vote.
Perrigo has higher revenue and earnings than Ultragenyx Pharmaceutical. Perrigo is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks.
Perrigo presently has a consensus target price of $40.67, indicating a potential upside of 49.24%. Ultragenyx Pharmaceutical has a consensus target price of $86.71, indicating a potential upside of 106.61%. Given Perrigo's higher probable upside, analysts plainly believe Ultragenyx Pharmaceutical is more favorable than Perrigo.
Perrigo has a net margin of -0.17% compared to Perrigo's net margin of -138.58%. Ultragenyx Pharmaceutical's return on equity of 6.96% beat Perrigo's return on equity.
Perrigo has a beta of 0.56, suggesting that its stock price is 44% less volatile than the S&P 500. Comparatively, Ultragenyx Pharmaceutical has a beta of 0.6, suggesting that its stock price is 40% less volatile than the S&P 500.
Summary
Ultragenyx Pharmaceutical beats Perrigo on 10 of the 18 factors compared between the two stocks.
Get Ultragenyx Pharmaceutical News Delivered to You Automatically
Sign up to receive the latest news and ratings for RARE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RARE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ultragenyx Pharmaceutical Competitors List
Related Companies and Tools
